1. Exposure to systemic glucocorticoid immunosuppression (gsISP) close to immune checkpoint inhibitor (ICI) initiation was associated with worse overall survival ...
1. Sequential and upfront treatment of metastatic colorectal cancer (mCRC) with oxaliplatin (OX)-based therapy does not lead to significantly different ...
1. Incidence of early-onset metastatic adenocarcinoma increased among patients with multiple metastatic sites and those with peritoneum involvement. 2. Net ...
1. Simvastatin (Zocor) in combination with paclitaxel (Taxol) is well tolerated and associated with significantly reduced disease progression compared to ...
1. The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic progression-free survival for metastatic hormone-sensitive prostate ...
Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that ...
1. Sitagliptin demonstrated the most prominent malignancy-related safety signal among the dipeptidyl peptidase-4 inhibitors studied. Evidence Rating Level: 2 (Good) ...
1. White House Chief of Staff Susie Wiles’ public breast cancer diagnosis is projected to drive a significant short-term increase ...
1. Pyrotinib combined with trastuzumab and docetaxel prolonged progression-free survival compared to placebo combined with trastuzumab and docetaxel in patients ...
1. Neoadjuvant immunoradiotherapy with camrelizumab and radiotherapy demonstrated favourable pathologic tumour regression and safety in the management of resectable locally ...
